Mental Health and Telehealth
Organizations and Professional Events
GH to GQZ

Since 2000 RGOc has operated as part of the university's Department of Psychiatry. In addition to its 75 multidisciplinary staff personnel, RGOc works with members of the University Hospital.

Objectives:

• Diagnose and/or confirm the diagnosis of multiple sclerosis
• Provide medical treatment and management for MS symptoms
• Promote mobility for disabled patients
• Minimize secondary complications
• Help patients maximize independence
• Assist patients and families in coping with the psychological implications of chronic disease
• Encourage patients and families to become part of the rehabilitation process
• Provide education and information about MS
• Provide referrals to other community services for people with MS

1. Global Addiction Conference (December 5-7, 2011: Lisbon, Distrito de Lisboa, Portugal)

Global Addiction Conference

Event sponsored by: Global Addiction

December 5-7, 2011
Lisbon, Distrito de Lisboa, Portugal

Topics:

• Neuroanatomy and Scanning
• Genetics
• Neurophysiology
• Diagnosis
• Epidemiology
• Pathology
• Drug Treatment
• Non-drug treatment
• Socio-economics

Featured speakers:

• David Nutt, Edmond J Safra Chair in Neuropsychopharmacology, Imperial College, London, UK; past president, European College of Neuropsychopharmacology
• Loretta P Finnegan, Medical Advisor, to the Director of the Office of Research on Women’s Health; Director, Community Prevention Study, Women's Health Initiative, National Heart, Lung and Blood Institute, National Institutes of Health [NIH], Department of Health and Human Services [DHHS], Bethesda, Maryland; Adjunct Professor of Pediatrics and Professor of Psychiatry and Human Behavior, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, US
• Karl Mann, Chair in Addiction Research, University of Heidelberg, Germany; President, International Society for Biomedical Research on Alcoholism [ISBRA]
• Michael Farrell, Director, National Drug & Alcohol Research Centre, University of New South Wales, Australia; Chair, Scientific Advisory Board, European Monitoring Centre on Drugs and Drug Dependence; Chair, Addictions Faculty, Royal College of Psychiatrists; Member, Expert Committee on Drug Dependence, World Health Organization [WHO]
• Julio Bobes, Professor and Chair of Psychiatry,University of Oviedo (Asturias); Clinical Director of Psychiatric Services, Oviedo Area, Spain
• Otto-Michael Lesch, President, Austrian Society of Addiction Medicine; Head, Addiction Medicine Research Group, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria
• Icro Maremmani, Professor of Addiction Medicine, University of Pisa; Professor of Addiction Medicine, University of Siena “Vincent P Dole”; Dual Diagnosis Group, Department of Psychiatry, Santa Chiara University Hospital, NFB University of Pisa, Italy; President, European Opiate Addiction Treatment Association [EUROPAD]; Board of Directors, Società Italiana Tossicodipendenze - Italian Society of Addiction Medicine [SITD-ItSAM]
• Andrej Kastelic, Head, National Center for the Treatment of Drug Addiction, Ljubljana; Head of co-ordination, Centers for the Prevention and Treatment of Drug Addiction, Ministry of Health, Republic of Slovenia; Secretary General, European Opiate Addiction Treatment Association [EUROPAD]; President, SEEA Society; President, SEE Adriatic Addiction Treatment Network

Deadline for abstracts or proposals: 9/30/2011.

Event Contact:

Russell Pendleton
Cortex Congress Limited
Lion House
51 Sheen Lane
London, SW14 8AB
United Kingdom

+44/20/8878 8289
+44/20/8388 0714

(A request: if inquiring about the above event, please say that you learned about it from these pages.)

An initiative is under way to expand the Consortium's network into a wider movement involving relevant international membership to improve needed synergy worldwide. GCAPP intends to serve as a catalyst, creating synergy across international organizations and borders to expand the capacity for developing, disseminating and implementing culturally tailored, effective interventions; to expand the knowledge base; and to facilitate advocacy and recognition, policy; delivery systems, training; and resources for mental health promotion and mental disorder prevention worldwide.

1. Advances in Neuropsychiatric Treatment (September 22-23, 2011: San Francisco, CA)

Advances in Neuropsychiatric Treatment

( Consult the meeting's Web pages.)

Sponsor: Global Technology Community [GTC]

September 22-23, 2011
San Francisco, CA

This conference will update practitioners in psychiatry, neurology, and primary care on the latest in neuropsychiatric theory and practice. Through a series of presentations led by industry leaders from the fields of medical research, academic research, pharmaceutical development, and biotech engineering, we will supply attendees with the latest developments in neuropsychiatric pathologies, epidemiologies, and treatment options.

The last decade has seen an impressive dissolution of the thin line dividing neurologic and psychiatric disorders. Today, the fields of neuropsychiatry and behavioral neurology are two of the fastest growing and are most vigorously researched specialties in the medical arena. The past year has seen an incredible increase in the elucidation of both the biological and functional underpinnings of numerous neuropsychiatric conditions, including depression, anxiety disorders, ageing-associated diseases, and degenerative diseases. With increased access to imaging and analytic techniques, novel on- and off-label treatment options are emerging on a near-monthly basis.

Topics:

• Neuroimaging Techniques for Drug Discovery
  • PET
  • fMRI
  • Spectrometry
  • Neuromapping
  • Utilizing Biomarkers
• Neuropsychiatric Therapeutics
  • Deep Brain Stimulation
  • Non-Invasive Stimulation
  • Transcranial Magnetic Stimulation
  • Synaptic Plasticity
  • Potential of Stem Cells
  • Personalized Medicine
• Cognition Across Neuropsychiatric Disorders
  • Depression
  • Schizophrenia
  • Anxiety Disorders
  • Autism Spectrum
  • Bipolar Disorder
  • Epilepsy
  • Dementia
  • Addiction
  • Sleep Disorders
• New Treatments Hiding in Glutamate Synapses
  • mGluRs
  • Allosteric Modulators
  • Neuromodulation
  • Novel Mechanisms
• The Role of Epigenetics and Genomics
  • Genome-Wide Association Studies
  • Advances in Genomics
  • New Discoveries from Epigenetics
• Lessons & Success in Clinical Trials
  • Overcoming Obstacles in Discovering Targets
  • Treatment Refractory Disorders
  • Case Study Success Stories

Presenters:

• David Bredt, MD PhD, Global Head, Neuroscience Discovery, Johnson & Johnson
• Mark Demitrack, MD, Vice President and Chief Medical Officer, Neuronetics
• Gül Dölen, MD PhD, Post-Doctoral Fellow, Psychiatry, Stanford University
• Fiona Gaughran, MD, Associate Clinical Director, Complex Care Pathway, Psychosis Clinical Academic Group
• Luis Hernandez-Garcia, PhD, Associate Professor, Biomedical Engineering, University of Michigan
• Gerard Marek, MD PhD, Project Director, Neuroscience Development, Abbott
• Dieter J Meyeroff, PhD, Professor of Radiology,, University of California San Francisco
• Cort A Pedersen, MD, Professor of Psychiatry, University of North Carolina School of Medicine
• Adam Savitz, PhD, Assistant Professor of Psychiatry,, Weill Cornell Medical College
• Phil Skolnick, PhD, Director, Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse [NIDA], National Institute of Health [NIH]
• Gabriel Vargas, MD PhD, Head, CNS Clinical Biomarkers, Amgen
• Min Zhang, PhD, Neuroscience Research, Abbott

Deadline for abstracts or proposals: 7/22/2011.

(A request: when you inquire about the above meeting, be sure to bring up our Web pages.)

Objectives:

• Provide knowledge about mental health to the public
• Provide mental health skills to interested citizens including Patients, Consumers, Carers, Volunteers
• Educate and train professionals in mental health practices
• Advance knowledge/research in the field
• Advocate for improved mental health and mental health services for the Gold Coast and Tweed communities